Sartorius pioneers continuous bioprocessing from single-use
The company's Pionic® platform with Sanofi aims to increase productivity threefold and reduce costs by 50%.
See the latest news and media coverage for Sartorius. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science and bioprocessing technology supplier
sartorius.comLast updated
In short: Sartorius maintained profitable growth through the first half of 2026, despite mid-year stock volatility and ongoing patent litigation.
The company's Pionic® platform with Sanofi aims to increase productivity threefold and reduce costs by 50%.
Sales up 6.4% constant currency, EBITDA margin 31.4%, confirms guidance.
Operational sales revenue grew 7.7% in constant currencies and underlying EBITDA margin rose to 30.3%.
The site more than doubles manufacturing capacity for cell and gene therapy materials, cost over €140 million, accommodates up to 180 employees, and operates without fossil fuels.
Sartorius Stedim Biotech SA (SDMHF) reports robust sales growth and improved margins, despite facing tariff-related headwinds and delayed orders.
Investing.com - The Sartorius preferred share falls to €215.30 (−2.93%) and is the weakest MDAX stock — a missed...
The Göttingen-based company Sartorius generated revenue of 1.811 billion euros in the first half of 2026 - an increase of 7.7 percent. But US tariffs cloud...
Recurring business remained the most important growth driver for both divisions. At the same time, the business stabilized ...
Track Sartorius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sartorius and other trending companies.